Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aditxt, Inc. - Common Stock (NQ: ADTX )

0.0201 -0.0133 (-39.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aditxt, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks – Aditxt Inc.’s (NASDAQ: ADTX) AditxtScore(TM) Featured in FedEx Video Presentation
Via Investor Brand Network
Exposures COVID-19
People with Autoimmune Disorders More Likely to Suffer Post-Heart Attack Complications, Study Finds
Via Investor Brand Network
FedEx Features AditxtScore™ Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health
From Aditxt, Inc.
Via Business Wire
Researchers Believe Seasonal Allergies Are Worsening
Via Investor Brand Network
Transplant Team at UW Medicine Completes Groundbreaking Surgery
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements
Via Investor Brand Network
Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Issues Corporate Update Following Reverse Stock Split, Closing of $20M Public Offering
Via Investor Brand Network
Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering
From Aditxt, Inc.
Via Business Wire
UBC Scientists Believe Insulin Tablet to Treat Diabetes May Soon Be Available
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering
Via Investor Brand Network
Aditxt Announces Closing of $20.0 Million Public Offering
From Aditxt, Inc.
Via Business Wire
The US Reaches One Million Organ Transplants
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Pricing of Public Offering
Via Investor Brand Network
Aditxt Announces Pricing of $20.0 Million Public Offering
From Aditxt
Via Business Wire
Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022
From Aditxt, Inc.
Via Business Wire
Researchers Find Link Between Steroidal Allergy Treatments, Decreased Brain Function
Via Investor Brand Network
Study Finds Children Have Better Outcomes with Kidney Transplants from Living Donors
Via Investor Brand Network
Study Finds That Early Exposure to Antibiotics May Trigger Asthma, Permanent Allergies
Via Investor Brand Network
Senate Review Reveals Screening Mistakes Caused Organ Transplant Failures, Illnesses, Deaths
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Looking to Solve Medical Challenge in Immune Responses
Via Investor Brand Network
Combining Immunotherapy with Anti-Rejection Drugs Can Treat Cancer, Prevent Kidney Transplant Rejection
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Bell2Bell Podcast
Via Investor Brand Network
Exposures COVID-19
Aditxt Inc. (NASDAQ: ADTX) Seeks to Address Variability of Immune Responses
Via Investor Brand Network
Study Finds That Introducing Some Foods to Infants Early Reduces Risks of Allergies
Via Investor Brand Network
Study Highlights New Insights on Neurological Autoimmune Illnesses
Via Investor Brand Network
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Moves One Step Closer to In-Human Trials with Completion of Preclinical Toxicity Study
Via Investor Brand Network
Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI™-100 Advancing it Closer to First-in-Human Trials
From Aditxt, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.